Recommended dosing schedules1:
MODERATE-TO-SEVERE ASTHMA WITH AN EOSINOPHILIC PHENOTYPE
OCS-dependent asthma or patients with comorbid moderate-to-severe atopic dermatitis for which DUPIXENT is indicated
- Initial dose is 600 mg (two 300 mg pre-filled syringes) followed 2 weeks later by every-other-week dosing of a 300 mg pre-filled syringe
DUPIXENT is intended for use under the guidance of a healthcare provider. A patient may self-inject DUPIXENT after training in subcutaneous injection technique using the pre-filled syringe. Provide proper training to patients and/or caregivers on the preparation and administration of DUPIXENT prior to use according to the Instructions for Use.
- DUPIXENT can be administered in the office under the guidance of a healthcare provider if the patient is not an appropriate candidate for self-administration
- DUPIXENT is also indicated for the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids
- a 300 mg=2 mL solution.
- b 200 mg=1.14 mL solution.